Immune Response In-Vitro In-Vivo Research 
Drug Discovery World
MAY 9, 2023
Jantzen Sperry , PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. Mice have long been heroes of preclinical cancer research. Cancer is far more complex than the sum of its parts.
The Pharma Data
JUNE 17, 2022
Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). However, immunocompromised individuals still lack effective immunity against SARS-CoV-2 infection.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 29, 2022
There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1, 6,7 This study also showed Evusheld reduced viral burden and limited inflammation in the lungs (in vivo) across all Omicron variants.6. Christoph D.
pharmaphorum
JANUARY 17, 2023
Research into mRNA dates back to the 1970s, but with the approval of both Moderna and BioNTech/Pfizer’s vaccines, this approach has finally been validated. Once its potential as a means of stimulating an immune response had been established, attention quickly turned to where else the technology could provide a therapeutic solution.
The Pharma Data
MARCH 25, 2022
Evusheld has the potential to provide long-lasting protection to vulnerable populations such as the immunocompromised who can’t mount an adequate response to a COVID-19 vaccine, and we’ll continue to work with governments in Europe to make Evusheld available as quickly as possible.”
Drug Discovery World
JULY 22, 2022
As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. Going beyond the limits of immune checkpoint inhibitors (ICIs). However, adverse effects such as cytokine release syndrome (CRS) and neurotoxicity still occur.
The Pharma Data
JANUARY 11, 2021
Xiaomin Fan, Founder, President and CEO of AvantGen, “Even with the recent Emergency Use Authorization of multiple vaccines, we believe there remains an urgent need for potent antibody therapies and prophylactics for immunocompromised patients who cannot mount an adequate immune response either to the vaccine or to subsequent viral infection.
Expert insights. Personalized for you.
52 
Let's personalize your content